Objective:
To discuss long-term data on the port delivery system (PDS) for neovascular age-related macular degeneration (nAMD) regarding vision maintenance, fluid control, safety, and refill intervals.
Approach:
- Long-term vision maintenance: Continuous therapy with the port delivery system maintains vision for 5 to 7 years with minimal dropoff compared to standard-of-care studies.
- Fluid control: 85% of patients showed no intraretinal fluid throughout the study, with retinal thickness remaining stable.
- Safety assessment: The incidence of endophthalmitis over 8 years was 2.8%, comparable to the cumulative risk from multiple injections.
- Refill intervals: Refill intervals vary; phase 3 studies suggest every 6 months, but some practitioners extend this to 9 months or even a year.
Key Findings:
- Continuous therapy with PDS shows sustained vision maintenance over 5 to 7 years.
- 85% of patients had no intraretinal fluid.
- The incidence of endophthalmitis is 2.8%, comparable to the risk from multiple injections over time.
- Refill intervals can be adjusted based on individual patient needs.
Limitations:
- The study's findings are based on specific trials and may not represent all patient populations.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.